Grants and Contributions:
Title:
COVID-19 Response: Development of a Rapid Test for COVID-19
Agreement Number:
947502
Agreement Value:
$49,414.00
Agreement Date:
Apr 1, 2020 - Aug 31, 2020
Description:
Sona is deploying its proprietary nanotechnology in the development of a rapid point-of-care (POC) test to screen for the current Coronavirus, COVID-19. The test will provide users with a quick-response lateral-flow test (LFT) to screen patients for the CoVID-19 virus. The test is expected to produce results in 5-15 minutes and is anticipated to be priced similarly to other LFT used to diagnose infectious diseases. There are currently no FDA approved lateral flow tests specific to CoVID-19. Due the significant need for a quick-response test, regulators such as the FDA are approving these assays through the emergency use authorization pathway. EUA is a path Sona will use in the future to make its test available in the US.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Halifax, Nova Scotia, CA B3J 3R7
Reference Number:
172-2020-2021-Q1-947502
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
821784832
Recipient Type:
For-profit organization
Recipient's Legal Name:
SONA NanoTech Ltd.
Federal Riding Name:
Halifax
Federal Riding Number:
12005
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325999